Verified factor-similar pair

IJJ vs XJH

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
85
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • IJJ has the higher backtested relative Sharpe (1.083 vs 0.705).
  • XJH has the lower published fee (0.12% vs 0.18%).
  • IJJ is cheaper on dividend valuation (109 vs 117, where 100 is each fund's historical median).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

IJJ

iShares S&P Mid-Cap 400 Value ETF
SMB
Adj. R2
0.946
Rel. Sharpe
1.083
Mkt beta
1.00
AUM
US$8.3B
MER
0.18%
Valuation
109

XJH

iShares ESG Select Screened S&P Mid-Cap ETF
SMB
Adj. R2
0.942
Rel. Sharpe
0.705
Mkt beta
1.02
AUM
US$362M
MER
0.12%
Valuation
117

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
IJJ
+0.54
|t|
+18.6
XJH
+0.54
|t|
+8.6
diff +0.01
HML
IJJ
+0.26
|t|
+8.7
XJH
+0.19
|t|
+3.2
diff +0.07
RMW
IJJ
+0.22
|t|
+6.7
XJH
+0.19
|t|
+2.9
diff +0.03
CMA
IJJ
+0.12
|t|
+2.7
XJH
-0.01
|t|
-0.1
diff +0.13
UMD
IJJ
-0.04
|t|
-2.3
XJH
+0.01
|t|
+0.2
diff -0.05

Why This Pair Matches

Exposure level
84
Exposure shape
99
Mkt beta diff
0.02
Rel. Sharpe diff
0.378

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

IJJ fund page XJH fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.